| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Giuseppe Pugliese | Q37382959 |
| Stefano Menini | Q43252011 | ||
| P2093 | author name string | Carla Iacobini | |
| Carlo M Pesce | |||
| P2860 | cites work | Human galectin-3 is a novel chemoattractant for monocytes and macrophages | Q22254736 |
| Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse | Q24309257 | ||
| Expression of galectin-3 modulates T-cell growth and apoptosis | Q24309392 | ||
| Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells | Q24530074 | ||
| Galectin-3 regulates myofibroblast activation and hepatic fibrosis | Q24546358 | ||
| Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3 | Q24624887 | ||
| Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis | Q24649584 | ||
| N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin | Q24651908 | ||
| Characterization of the advanced glycation end-product receptor complex in human vascular endothelial cells | Q28138960 | ||
| Intracellular functions of galectins | Q28201120 | ||
| SR proteins and galectins: what's in a name? | Q28286108 | ||
| Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease | Q28534290 | ||
| Epsilon BP, a beta-galactoside-binding animal lectin, recognizes IgE receptor (Fc epsilon RI) and activates mast cells | Q28572966 | ||
| Immune-mediated beta-cell destruction in vitro and in vivo-A pivotal role for galectin-3 | Q28574963 | ||
| CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity | Q29617380 | ||
| Composition of the stable carotid plaque: insights from a multidetector computed tomography study of plaque volume | Q30434380 | ||
| Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation | Q32058522 | ||
| Impaired retinal angiogenesis in diabetes: role of advanced glycation end products and galectin-3. | Q45285377 | ||
| Advanced lipoxidation end-products mediate lipid-induced glomerular injury: role of receptor-mediated mechanisms. | Q46067855 | ||
| Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils | Q46320323 | ||
| Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. | Q46323175 | ||
| Galectin-3 is a negative regulator of lipopolysaccharide-mediated inflammation | Q46442221 | ||
| At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products | Q46450292 | ||
| A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury | Q46461255 | ||
| Development of age-dependent glomerular lesions in galectin-3/AGE-receptor-3 knockout mice. | Q46471398 | ||
| CD36 is not involved in scavenger receptor-mediated endocytic uptake of glycolaldehyde- and methylglyoxal-modified proteins by liver endothelial cells | Q46535587 | ||
| The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis | Q47703344 | ||
| Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. | Q47999828 | ||
| Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. | Q48024001 | ||
| Activation of the Receptor for Advanced Glycation End Products Triggers a p21 -dependent Mitogen-activated Protein Kinase Pathway Regulated by Oxidant Stress | Q50180621 | ||
| Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. | Q52574179 | ||
| Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue. | Q53576992 | ||
| Galectin-3 drives glycosphingolipid-dependent biogenesis of clathrin-independent carriers | Q57274173 | ||
| Grand challenges in chronic non-communicable diseases | Q59055681 | ||
| A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection | Q59068486 | ||
| Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial | Q44459441 | ||
| Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. | Q45052723 | ||
| N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells | Q45178590 | ||
| Galectin-3 is a new MerTK-specific eat-me signal | Q33972695 | ||
| Inflammation: the link between insulin resistance, obesity and diabetes | Q34286695 | ||
| Advanced protein glycosylation in diabetes and aging | Q34298835 | ||
| Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis | Q34316944 | ||
| Galectins as modulators of cell adhesion | Q34346487 | ||
| Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction | Q34364121 | ||
| Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study | Q34370169 | ||
| Osteoblast and chondroblast differentiation. | Q34373196 | ||
| Galectins as modulators of tumour progression | Q34381235 | ||
| The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses | Q34387881 | ||
| Galectin-3: an open-ended story | Q34494555 | ||
| Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis | Q34501897 | ||
| Galectin binding to Mgat5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells | Q34563122 | ||
| Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice | Q34603941 | ||
| T-cell growth, cell surface organization, and the galectin-glycoprotein lattice | Q34691040 | ||
| Identification of galectin-3 as a factor in pre-mRNA splicing | Q34706659 | ||
| The regulation of inflammation by galectin-3. | Q34991925 | ||
| Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque | Q35151273 | ||
| Critical role of galectin-3 in phagocytosis by macrophages | Q35169042 | ||
| Role of galectin-3 in diabetic nephropathy | Q35182376 | ||
| Transcriptional analysis of the endothelial response to diabetes reveals a role for galectin-3. | Q35553234 | ||
| Regulation of cellular homeostasis by galectins | Q35646643 | ||
| Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. | Q35809897 | ||
| Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation | Q36069797 | ||
| Understanding RAGE, the receptor for advanced glycation end products | Q36245387 | ||
| Anatomical differences and atherosclerosis in apolipoprotein E-deficient mice with 129/SvEv and C57BL/6 genetic backgrounds | Q36296729 | ||
| Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice | Q36357458 | ||
| Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients | Q36727795 | ||
| In vivo analysis of Wnt signaling in bone | Q36774960 | ||
| Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. | Q36887564 | ||
| The mucopolysaccharidoses: a success of molecular medicine. | Q37059193 | ||
| Oxidation-specific epitopes are important targets of innate immunity | Q37138021 | ||
| Interleukin-10 prevents diet-induced insulin resistance by attenuating macrophage and cytokine response in skeletal muscle. | Q37400702 | ||
| Adaptive regulation at the cell surface by N-glycosylation. | Q37598972 | ||
| Metabolism, cell surface organization, and disease | Q37671886 | ||
| A role for the NLRP3 inflammasome in metabolic diseases--did Warburg miss inflammation? | Q37995073 | ||
| Epidemiology of diabetic kidney disease | Q38071780 | ||
| Cross-linking of galectin 3, a galactose-binding protein of mammalian cells, by tissue-type transglutaminase | Q38298480 | ||
| S-type mammalian lectins in allergic inflammation | Q38315519 | ||
| Adipose tissue-specific modulation of galectin expression in lean and obese mice: evidence for regulatory function | Q38317758 | ||
| L-29, an endogenous lectin, binds to glycoconjugate ligands with positive cooperativity | Q38322449 | ||
| Galectin-3 stimulates cell proliferation | Q38330513 | ||
| Role of the carboxyl-terminal lectin domain in self-association of galectin-3. | Q38338168 | ||
| Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes | Q38346878 | ||
| Galectin-3 binds lactosaminylated lipooligosaccharides from Neisseria gonorrhoeae and is selectively expressed by mucosal epithelial cells that are infected | Q38362263 | ||
| Open Wound Healing In Vivo: Monitoring Binding and Presence of Adhesion/Growth-Regulatory Galectins in Rat Skin during the Course of Complete Re-Epithelialization | Q38978059 | ||
| Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice | Q39191329 | ||
| A possible suppressive role of galectin-3 in upregulated osteoclastogenesis accompanying adjuvant-induced arthritis in rats | Q39915429 | ||
| Galectin-3 regulates integrin alpha2beta1-mediated adhesion to collagen-I and -IV. | Q39937520 | ||
| 111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors | Q39991883 | ||
| Regulation of alternative macrophage activation by galectin-3. | Q40016366 | ||
| Contributions of galectin-3 and -9 to epithelial cell adhesion analyzed by single cell force spectroscopy | Q40098307 | ||
| Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. | Q40147884 | ||
| Implication of galectin-3 in Wnt signaling. | Q40427814 | ||
| Characterisation of the advanced glycation endproduct receptor complex in the retinal pigment epithelium | Q40477757 | ||
| Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. | Q40508811 | ||
| Galectin-3, a novel binding partner of beta-catenin | Q40514776 | ||
| Expression of galectin-3 in skeletal tissues is controlled by Runx2. | Q40668407 | ||
| The family of metazoan metal-independent beta-galactoside-binding lectins: structure, function and molecular evolution | Q40860039 | ||
| Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets | Q40944709 | ||
| Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts | Q41009444 | ||
| Galectin-3 gene (LGALS3) expression in experimental atherosclerosis and cultured smooth muscle cells. | Q41020090 | ||
| Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease | Q41134548 | ||
| Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil function. | Q42046253 | ||
| Endocytic uptake of advanced glycation end products by mouse liver sinusoidal endothelial cells is mediated by a scavenger receptor distinct from the macrophage scavenger receptor class A. | Q42158174 | ||
| Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor | Q42467384 | ||
| The diabetic milieu modulates the advanced glycation end product-receptor complex in the mesangium by inducing or upregulating galectin-3 expression. | Q42491067 | ||
| Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. | Q42767408 | ||
| Specific siRNA targeting the receptor for advanced glycation end products inhibits experimental hepatic fibrosis in rats | Q43187791 | ||
| Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes | Q43191933 | ||
| Do advanced glycation end products contribute to the development of long-term diabetic complications? | Q43458994 | ||
| Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats | Q43508619 | ||
| Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. | Q43786750 | ||
| Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - amelioration by liver transplantation. | Q43862536 | ||
| Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways | Q44368608 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 136-150 | |
| P577 | publication date | 2014-10-09 | |
| P1433 | published in | Glycobiology | Q5572596 |
| P1476 | title | Galectin-3: an emerging all-out player in metabolic disorders and their complications | |
| P478 | volume | 25 |
| Q38663550 | A GalNAc/Gal-specific lectin from the sea mussel Crenomytilus grayanus modulates immune response in macrophages and in mice. |
| Q90185480 | Benefits of physical exercise on cognition and glial white matter pathology in a mouse model of vascular cognitive impairment and dementia |
| Q90134675 | Berberine inhibits adipocyte differentiation, proliferation and adiposity through down-regulating galectin-3 |
| Q36877555 | Circulating Galectin-3 Is Associated With Cardiometabolic Disease in the Community |
| Q57494712 | Clinical physiology and sleep: highlights from the European Respiratory Society Congress 2018 presented by early career members |
| Q89551039 | Dietary Synbiotic Supplementation Protects Barrier Integrity of Hepatocytes and Liver Sinusoidal Endothelium in a Mouse Model of Chronic-Binge Ethanol Exposure |
| Q47810391 | Enzymatic Synthesis of N-Acetyllactosamine (LacNAc) Type 1 Oligomers and Characterization as Multivalent Galectin Ligands. |
| Q38297428 | Galectin Binding to Neo-Glycoproteins: LacDiNAc Conjugated BSA as Ligand for Human Galectin-3. |
| Q28069174 | Galectin-3 and IL-33/ST2 axis roles and interplay in diet-induced steatohepatitis |
| Q64097454 | Galectin-3 as a prognostic biomarker for diabetic nephropathy |
| Q102152223 | Galectin-3 gene deletion results in defective adipose tissue maturation and impaired insulin sensitivity and glucose homeostasis |
| Q33754984 | Galectin-3 in Peripheral Artery Disease. Relationships with Markers of Oxidative Stress and Inflammation. |
| Q57131309 | Mechanistic targeting of advanced glycation end-products in age-related diseases |
| Q55122769 | Microglia activation and phagocytosis: relationship with aging and cognitive impairment in the rhesus monkey. |
| Q30235846 | Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. |
| Q38705659 | Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies |
| Q33897327 | Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3. |
| Q40085529 | Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients |
| Q47133991 | Role of Galectin-3 in Bone Cell Differentiation, Bone Pathophysiology and Vascular Osteogenesis. |
| Q26771826 | Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis |
| Q27010462 | Role of receptor for advanced glycation end products (RAGE) in liver disease |
| Q38807532 | Sugared biomaterial binding lectins: achievements and perspectives |
Search more.